The trial will assess if the drug may be able to prevent infection among patients who have been exposed and treat those who have been infected with...
During the 2018 outbreak of Ebola, Regeneron quickly developed a promising monoclonal antibody triplet therapy that’s now under review by the FDA. ...
Hospitals need to find space and staff to administer the drug at a time when there’s hardly enough of either to treat those who are sick.
Injections of antibodies might prevent mild COVID-19 from becoming severe, but the treatments are expensive and difficult to make.
Create
Sign in to save articles, videos, notes, and other finds.